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Abstract
Podocalyxin (Podxl) is a type I membrane sialoprotein of the CD34 family, originally described in the epithelial glomerular
cells of the kidney (podocytes) in which it plays an important function. Podxl can also be found in megakaryocytes and
platelets among other extrarenal places. The surface exposure of Podxl upon platelet activation suggested it could play
some physiological role. To elucidate the function of Podxl in platelets, we generated mice with restricted ablation of the
podxl gene in megakaryocytes using the Cre-LoxP gene targeting methodology. Mice with Podxl-null megakaryocytes did
not show any apparent phenotypical change and their rates of growth, life span and fertility did not differ from the floxed
controls. However, Podxl-null mice showed prolonged bleeding time and decreased platelet aggregation in response to
physiological agonists. The number, size-distribution and polyploidy of Podxl-null megakaryocytes were similar to the floxed
controls. Podxl-null platelets showed normal content of surface receptors and normal activation by agonists. However, the
mice bearing Podxl-null platelets showed a significant retardation in the ferric chloride-induced occlusion of the carotid
artery. Moreover, acute thrombosis induced by the i.v. injection of sublethal doses of collagen and phenylephrine produced
a smaller fall in the number of circulating platelets in Podxl-null mice than in control mice. In addition, perfusion of
uncoagulated blood from Podxl-null mice in parallel flow chamber showed reduced adhesion of platelets and formation of
aggregates under high shear stress. It is concluded that platelet Podxl is involved in the control of hemostasis acting as a
platelet co-stimulator, likely due to its pro-adhesive properties.
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Introduction
Podocalyxin (Podxl), also known as Myb-Ets transformed
progenitor (MEP), is a ,160 KDa, highly sialylated and sulfated,
membrane type I mucoprotein of the CD34 family [1]. This
protein was first reported in the epithelial cells, podocytes, lining
the luminal face of kidney glomeruli [2]. The podocytes are
injured in many glomerular diseases, including minimal change
disease (MCD), focal segmental glomerulosclerosis (FSGS),
collapsing glomerulopathy, diabetic nephropathy, membranous
glomerulopathy, crescentic glomerulonephritis, and lupus nephri-
tis [3–5]. Those inflammatory processes are accompanied by loss
of the normal architecture, ‘‘effacement’’, of the luminal surface of
podocytes and loss of the urinary filtration slits [3,6]. Moreover,
total podocalyxin knock out mice die of anuria within the first few
hours after birth [7]. Podxl has also been found in vascular
endothelium, lung, brain, multipotent hematopoietic precursors
and platelets [8–10], and in several types of tumors in which the
expression levels appear to correlate with the metastatic capacity
[11–13]. Despite the consistent data indicating the important role
played by Podxl in maintaining a normal renal function, almost
nothing is known about its physiological role in extrarenal tissues.
Podxl is exposed on the plasma membrane of platelets upon
stimulation by agonists [14] suggesting that it could cooperate in
maintaining a normal hemostatic responsiveness. Moreover, the
loss-of-function mutation (plt1 mice) in the glycoprotein-N-
acetylgalactosamine-3-galactosyltransferase (C1GalT1), essential
for the synthesis of extended mucin-type O-glycans, produced
underglycosylation of podocalyxin and glycoprotein Ib (GPIb) and
caused thrombocytopenia and kidney disease, suggesting a
contribution of the abnormally glycosylated Podxl to this
pathology [15]. In agreement with these observations, we have
recently reported a diminished adhesion of sialic acid deficient O-
glycomutant CHO-Podxl cells compared with cells expressing
normal sialylated Podxl [16]. These antecedents suggest that
Podxl, like other mucin proteins, could play a role in cell
adhesion/migration. In fact, a particular glycosylation pattern of
Podxl could be responsible for the ability of high endothelial
venules to bind L-selectin from other cells [17–19]. Moreover,
CHO cells expressing recombinant human Podxl showed, P-
selectin and integrin-dependent, enhanced adhesion and motility
over immobilized ligands and increased cellular interactive
capacity [16].
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26025The present work aimed at investigating the functional role of
Podxl in platelets. For this purpose, we used the Cre-LoxP gene
targeting methodology to generate mice with specific ablation of
the podxl gene in megakaryocytes. Mice with null-Podxl megakar-
yocytes showed prolonged bleeding time, decreased platelet
aggregation in response to agonists, retarded ferric chloride-
induced closure of the carotid artery, diminished in vivo
thrombogenesis and decreased adherence of platelets under flow.
These observations suggest that removal of the podxl gene from
megakaryocytes perturbs the control of hemostasis.
Methods
Animals
Mice of the C57BL/6 strain, maintained under controlled
conditions of light and temperature, were used in all the
experiments. Podxl
lox/lox:: Control or Podxl
lox/lox:: Pf4-Cre
littermates used in this study were generated on a mixed
C57BL/6-129sv genetic background and were backcrossed for
10 generations with C57BL/6 mice. All animal experiments were
done in such a way as to minimize the animal suffering, according
to relevant national and international guidelines (‘‘Guide for Care
and Use of Laboratory at the Institute of Laboratory Animal
Resources’’).
The ethics committee of the Center for Biological Research
(CSIC) and the grant review board (ANEP) of the Spanish
Ministry of Science and Technology specifically approved this
study in accordance with the guidelines of the European
Community Council Directive 86/609 EEC.
Generation of a conditional (floxed) podocalyxin allele
The DNA sequence of the podocalyxin gene was obtained by
digestion of the murine genomic BACS 449o15 and 465p05 with
BamHI ,EcoR I and Xba I. DNA fragments containing the podxl
gene were identified by southern blot and cloned. Digestion of
clone 465p05 with Sac I released a 4,381 bp fragment comprising
exons 3 to 8 of podxl that was cloned into the Sac I site of pCR 2.1-
TOPO.
A conditional podxl transgene was built in three steps into the
pBS II vector using the pLox plasmids [20], as shown in Fig. 1.
The pLoxL contained the left homology arm (exons 3 and 4 of
podxl); the pLoxC encompassed exons 5 to 7 of podxl flanked by
LoxP sites and neo (PGK-NEO) and tk (HSV-TK) selection
cassette; the pLoxR contained the right homology arm (exon 8 and
part of the 39-UTR of podxl) and a counterselection cassette for the
diphteria toxin A chain (PGK-DT).
The left homology arm was generated by Sac I digestion of
the genomic DNA fragment containing the podxl gene and
amplification with oligonucleotide primers LoxL-S (59-
CCGAATTCCGCCTGCCTCAGCC-39) to introduce an EcoR
I site, and LoxL-AS (59-GGATGCATTATCATGCCT-
CAGCTGG-39) to replace the site AlwN I by a Nsi I site. The
PCR product was cloned into AccepTor-Vector (AccepTor Vector
Kits, Novagen). The pLoxL vector was modified by means of
adapters to clone the PCR product into the EcoR I and Nsi I sites.
The genomic DNA fragment containing exon 8 and 39-UTR of
the podxl gene was amplified using oligonucleotides LoxR-S
(59-TCATGCATGCTTGTCTCTAACGCTG-39) to replace
a Nsi I site for Nhe I, and LoxR-AS (59-GCTCTAGA
GTGCAGTTGGGGTG-39) that replaces a Sac I site for a Xba
I. The PCR product was cloned in the AccepTor-Vector. We
introduced an adapter into the pLoxR vector to generate Nsi I site
for subcloning of the podxl right homology arm.
To generate the ‘‘floxed’’ fragment (exons 5 to 7 of podxl)w e
amplified a DNA fragment comprising exons 5 to 7 from the Sac I
genomic DNA fragment using primers LoxC-S (59-TACTG-
CAGCTGGGTCCAGAGCCTTA-39) designed to replace the
restriction site AlwN I by a Pst I site, and LoxC-AS (59-
AGCTGCAGTGACAGCGGGGACAAGA-39) to replace an
Nhe I site by Pst I site. The PCR product was cloned into
AccepTor-Vector, released by digestion with Pst I, and cloned into
the Nsi I site of the vector pLoxL. The pLoxC vector was digested
with Not I and Sse I to clone the left homology arm and ‘‘floxed’’
fragments upstream of the neo and tk selection cassette. Finally, the
Not I-Asc I fragment was subcloned upstream of the right homology
arm in the pLoxR vector.
The final construction was sequence-verified using the following
primers:
MPDL 939–957 (59-GAGATGAGGTGTGTGAACT-
39)
MPDL 1053-1031 (59-CTTATGGGAGGTTCA-
CAGTT-39)
MPDU 3 (59-GACTAGCCATGCCTGAGTTTG -39)
MPDU 1100 (59-TGGTGGGGCTGCACTGCATA-
39)
MPDL 1272-1254 (59-CGGCCTTAGGAGAAA-
GCTTCG39)
MPDU 1211-1192 (59-CTCTACATGTGGCCCC-
TATT-39)
MPDU 1338-1318 (59-CGGAGTCAGTGACAT-
GAAGCT-39)
MPDL i1484 (59-ACTGTCTTAATGCTCTCATT-39)
MPDL 1505-1486 (59-CAGCTCCTCTGTGAGC-
CGTT-39)
MPDU i7 (59-TGAGATGGTCAGGCTAGTAGC-39)
Generation of mice with a floxed podxl gene
R1 E14 (129/Sv) embryonic stem (ES) cells, kindly donated by
Dr. Nagy, were cultured according to their indications [21].
Twenty-five mg of the podxl construct were electroporated into ES
cells. Positive selection was achieved with G418 (Sigma) at a
concentration of 250 mg/mL and the resistant ES cell clones were
screened for homologous recombination by PCR. The modified
ES cells were expanded and transfected with the p-MC-Cre
plasmid in order to remove the selection cassette (neo and tk).
Finally, ES cells carrying the ‘‘floxed’’ podxl allele were used for
morula aggregation to generate chimeric mice according to
previous protocols [22]. Genotyping was carried out by PCR.
Two founders were subsequently used for further analysis.
To generate mice with a restricted deletion of Podxl in platelets,
the Podxl floxed mice were crossed to Pf4-Cre mice [23] (kindly
donated by Dr. Skoda, Basel).
Hemograms and tail bleeding time
Hemograms were determined in blood-EDTA samples with-
drawn from the submaxillary vessels, using an automatic
hemocytometer model Abacus Junior (Diatron, Diatron Mes-
stechnik GmbH, Austria).
To determine the tail bleeding time the animals were
anesthetized with isofluorane. The tail was transected at 5 mm
from the tip and it was immediately immersed in 36uC phosphate
buffered saline (PBS), and the time until cessation of bleeding
recorded.
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The carotid artery blood flow was determine in mice
anesthetized with isofluorane, while maintained the body temper-
ature at 37uC on a heated blanket. The temperature was
continuously recorded using a rectal miniprobe. The carotid
artery was exposed and the blood flow measured with a 0.5 mm
micro-flow probe (0.5 PBS) and the TS420 flow module
(Transonic Systems, Inc., Ithaca, NY). The data was continuously
recorded with a data acquisition system PowerLab 8/30, model
ML870 (AD Instruments Ltd., Chalgrove, Oxfordshire OX44
7RW, UK).
To determine the carotid artery closure time, a 1 mm
2 paper
fragment soaked on 2% ferric chloride was placed for 2 minutes
on the exposed carotid artery while the blood flow was
continuously monitored. We considered the closure time to be
that at which the blood-flow was interrupted for 3 minutes.
Preparation and activation of platelets
Citrated blood samples were obtained by cardiac puncture
under isofluorane anesthesia. The blood was centrifuged at 100 g
for 5 minutes at room temperature. Platelet-rich plasma (PRP) was
removed and centrifuged at 1300 g in the presence of 0.1 mg/mL
prostacyclin and 0.02 U/mL apyrase (Sigma) for 5 minutes at
room temperature, washed 3 times with modified Tyrode’s buffer
containing 0.1 mg/mL prostacyclin and 0.02 U/mL apyrase. The
sedimented platelets were finally resuspended in Tyrode’s buffer
containing 0.02 U/mL apyrase and rested for 30 minutes at 37uC
prior to stimulation.
The membrane content of surface receptors was determine in
washed platelets, incubated with anti–GPIba–DyLight649 anti-
body (Xia.G5), anti aIIbb3-FITC (Leo.F2), FITC-labeled rat anti-
mouse GPVI and FITC-labeled rat anti-mouse integrin alpha2
chain (CD49b) (Emfret Analytics, Eibelstadt, Germany) or control
isotype-matched mouse IgGs for 30 minutes at room temperature.
The samples were then washed and fixed with 1% formaldehyde,
and analyzed in a cytometer EPICS XL FACS.
To determine the extent of platelets activation, 25 mLo fw a s h e d
platelets (10
6 approximately) suspended in Tyrode’s-buffer containing
1m M C a C l 2 were stimulated with ADP, thrombin or collagen.
Activation was assessed by determining P-selectin exposure and aIIbb3
activation by flow cytometry (cytometer model FC500) with a two-
color analysis protocol using 5 mL of Dylight 649 anti-GPIba moAb
(Emfret Analytics) and 5 mL of FITC-anti-P-selectin (Beckton and
Dickinson) or PE-anti-activated aIIbb3 (JON/A, Emfret Analytics)
moAbs. The extent of platelet activation was further assessed by
measuring the surface exposure of phosphatidylserine, as indicated by
the binding of FITC-Annexin V (Immunostep, Salamanca, Spain).
Determination of prothrombin time (PT) and activated
partial thromboplastin time (aPTT)
The concentration of PT and aPTT were determined in plasma
samples in a coagulometer (Start4, Diagnostica Stago) according to
the protocols of the manufacturer. Briefly, PT was determine by
adding 100 mL of Neoplastin (Roche) to 50 mL of plasma; to
determine aPTT, 50 mL of plasma were mixed with 50 mLo f
aPTT reagent (Roche) in the presence of CaCl2.
Figure 1. Podocalyxin gene targeting construct. Deletion of the podxl gene. Generation of the floxed podxl allele was performed as described in
Methods. Circled numbers indicate the order of the different steps in the construction of the final chimera.
doi:10.1371/journal.pone.0026025.g001
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The aggregation of platelets in whole blood collected in the
presence of PPACK (40 mg/mL) was performed measuring the
changes in impedance (Ohms) produced by physiological agonists
in a Chrono-Log instrument. Samples were incubated at 37uC
under constant stirring and, after 5 minutes, 10 mM ADP or 5 mg/
mL collagen (Chrono-Log) were added. The analysis of data was
performed 8 minutes after addition of agonists. The results are
means 6SEM of seven different observations in each group.
Collagen-induced aggregation ofisolated platelets wasmeasured in a
final volume of 800 mL of PRP diluted to 1:2 with PBS buffer.
Platelet adhesion and spreading assays
To determine the adherence of platelets to immobilized ligands
100 mLo f5 610
8 platelets/mL were added to 96-well microtiter flat-
bottomed plates coated with fibrinogen (5 mg/mL) and incubated at
37uC for 30 minutes. Non-adherent platelets were removed by
aspiration and wells were washed 3 times with 200 mLo fP B Sb u f f e r .
To study the platelet spreading 100 mL of a platelet suspension
containing 5610
7/mL platelets was added to microtiter plates
coated with fibrinogen (5 mg/mL) and allowed to adhere for
1 hour at 37uC. Non adherent cells were removed by washes with
PBS buffer. The adhered platelets were fixed with 3.7% PFA,
permeabilized with 0.2% Triton X-100 in PBS buffer, washed
twice with PBS and stained for F-actin with FITC-conjugated
phalloidin for 20 minutes and washed at least 3 times with PBS.
Fluorescence was visualized using an Olympus IX-50 inverted
microscope with a monochromatic light source and images taken
with a DP70 digital camera (Olympus). The images were analyzed
using the ImageJ software [24].
In vitro perfusion experiment
To analyze the formation of platelet thrombi we perfused whole
blood diluted to 1:2 with Tyrode’s buffer containing 1% of serum
albumin, through parallel plastic chambers (Ibidi, Germany) coated
with fibrinogen. Blood was perfused by aspiration with a syringe pump
(Harvard Apparatus) at an estimated shear stress of 5 dyne/cm
2 (m-
slide III 0.1 Luer) or 20 dyne/cm
2 (m-slide I 0.1 Luer). Images were
taken with an Olympus digital camera. The quantification of platelets
a d h e r e dt oi m m o b i l i z e ds u b s t r a t e s was carried out with the ImageJ
software [24]. We first generated a list of the total number of particles
without setting any limits to size or circularity. The particles were
sorted by size. We had previously estimated the size of a platelet to be
,900 pixels.We, then,sorted the aggregatesin the groupsaccordingto
their sizes: small, between 1000–5000 pixel; intermediates, 5000–
10000 pixel; large, 10000–30000, and, finally, very large aggregates,
greater than 30000 pixel.
To assess adhesion of platelets onto immobilized collagen under
flow conditions, ,25610
6 washed platelets suspended in Tyrode’s
Figure 2. Deletion of the podocalyxin gene in megakaryocytes. (A) PCR amplification of genomic DNA from either control or Podxl-null
megakaryocytes. (B) In left panel, western blot of megakaryocyte lysates. In upper right panels, immunofluorescence of control and Podxl-null
megakaryocytes labeled with anti-Podxl. In lower panels, megakaryocytes from normal of Podxl-null mice stained for F-actin with labeled phalloidin.
Fluorescence was visualized using an Olympus IX-50 inverted microscope with a monochromatic light source and images taken with a DP70 digital
camera (Olympus).
doi:10.1371/journal.pone.0026025.g002
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mL) (Molecular Probes, Invitrogen). The labeled platelets were
perfused through a parallel flow chamber (m-slide VI 0.1 Luer)
precoated with 100 mg/mL of collagen (Chrono-log) at an
estimated shear stress of 20 dyne/cm
2. Non-adhered platelets
were removed by washing the chamber with PBS for 5 minutes.
To quantify the number of platelets adhered onto collagen the
perfusion channel was washed with 50 mL of DMSO and its
fluorescence determined. As a blank we used DMSO passed
through a collagen coated cell-free perfusion chamber.
Studies of thrombogenesis in vivo
Mice were anesthetized with isofluorane and the yugular veins
exposed. A small sample of blood (#100 mL), extracted from one
of the yugular veins, was dropped into a tube containing EDTA
and the number of platelets at zero determined in a hemocytom-
eter analyzer Abacus Junior (Diatron Messtechnik GmbH,
Austria). Through the same vein we injected a mixture of
collagen/epinephrine (150 ng collagen type I (Chronolog) and
15 ng epinephrine (SIGMA) per g of mice body weight). In
preliminary experiments we could observe that this proportionate
amount of reagents produced a significant drop in the number of
circulating platelets without causing the death of the animal. At
the indicated time after the injection, blood withdrawn from the
yugular vein not previously injected was processed as indicated
above and the number of platelets determined.
Detection of podxl gene deletion and Podxl protein
The correct recombination of the podxl gene was verified by PCR
analysis of genomic DNA extracted from isolated megakaryocytes.
The presence of Podxl protein in megakaryocytes was analyzed by
western blot using specific monoclonal antibodies [25].
Megakaryocyte quantification
Mice were perfused through the heart with PBS followed by 4%
PFA in PBS and the femurs were immersed in 4% PFA-PBS
overnight. The fixed femurs were decalcified and pictures of whole
longitudinal sections were taken under light microscope at 206
using a DP70 digital camera mounted on as inverted microscope
(IX50, Olympus). The area of megakaryocytes was calculated using
the ImageJ software and the cells classified in 5 different groups
accordingto their size. A total of two hundred megakaryocytes from
either control or Podxl-null mice were analyzed.
In vitro differentiation of megakaryocytes
Bone marrow cells were flushed from femurs and tibias with
Tyrode’s buffer, dissociated and cultured in IMDM with 5% fetal
bovine serum, 50 ng/mL TPO, 2 mM L-glutamine, 50 U/mL
penicillin, and 50 mg/mL streptomycin. Megakaryocytes were
Figure 3. Size and DNA distribution of megakaryocytes in situ
and differentiated in vitro. Megakaryocytes from a decalcified femur
(A) and from a bone marrow culture (B). Because the number of
megakaryocytes was similar in control and Podxl- null mice, for the sake
of clarity, only images from the controls are represented. Size
distribution of megakaryocytes in situ (C) or in culture (D) determined
by wide-field microscopy. Formation of proplatelets in control (E) or in
Podxl-null mice (F). DNA distribution in control (G) or Podxl-null
megakaryocytes (H).
doi:10.1371/journal.pone.0026025.g003
Table 1. Bleeding and carotid closure times.
Bleeding time (s) Carotid closure time (s)
Control 40625(12) 441625(8)
Podxl-null 263681(8) 9226186(8)
% increment 87% 109%
p,0.05 p,0.01
Bleeding time was measured in animals anesthetized by isofluorane inhalation.
A small fragment of the tail (approx. 5 mm) was excised and the tail immersed
in isotonic buffer at 37uC, recording the time until bleeding stopped. The
carotid closure time was determined by placing a small piece of paper
(,1m m
2) soaked with 2% FeCl3 onto the artery for two minutes and the blood
flow was continuously monitored. A closure time was defined as the time
needed for the blood flow be stopped at least for three minutes. The number of
observations is shown in parentheses.
doi:10.1371/journal.pone.0026025.t001
Table 2. Fall in circulating platelets induced by the i.v.
injection of collagen and phenylephrine.
Time (min) 0 29 % Fall in blood platelets
Control 909.4690.7 398.3650.3 56.562.9
Podxl-null 825.6663 433.1624.9 46.863.6*
Blood was collected from the yugular vein of isofluorane-anesthetized mice
followed by i.v. injection of 150 ng collagen type I plus 15 ng of epinephrine
per g of mice body weight, as described in Methods. At the indicated time
blood was withdrawn from the contralateral yugular vein and the number of
platelets determined. Seven animals were analyzed in each group. The values
are means 6SEM. By t-test * p,0.05.
doi:10.1371/journal.pone.0026025.t002
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density gradient of albumin.
Megakaryocytes ploidy
TPO-differentiated megakaryocytes were labeled with a FITC-
conjugated anti-CD41 antibody. The cells were fixed in 70% ice-cold
ethanol and stained with propidium iodide solution (50 mg/mL) in
t h ep r e s e n c eo fR N A s eA( 1 0 0mg/mL). The ploidy distribution was
determined by 2-color flow cytometry (FACS EPICS XL).
Megakaryocyte adhesion and proplatelet formation
TPO-differentiated megakaryocytes were seeded onto collagen-
coated coverslips (100 mg/mL), allowed to adhere for 3 hours at
37uC,andfixed in2%PFAfor15 minutes.Thecellswereincubated
withblockingbuffer(0.2%BSA,0.02%saponininPBS).Stressfibers
were labeled by incubating the cells with phalloidin-AF488 (1/40).
The percentage of megakaryocytes forming proplatelets was
determined by differential interference contrast (DIC) microscopy
using a Leica inverted microscope (objective 406/0.55; Leica
Microsystems). Several photographs of the cell were taken and
analyzed. Megakaryocytes were examined from 3 independent
cultures.
Results
The ablation of the podxl gene in megakaryocytes resulted in no
apparent phenotype and the rates of growth and fertility were
normal. To assess the presence of the podxl gene, we amplified
genomic DNA from megakaryocytes of either control (podxl
lox/lox::
Control) or Podxl-null mice (podxl
lox/lox:: Pf4-Cre). Floxed allele
yielded a fragment of 1,700 bp whereas the deleted allele generated
a fragment of 450 bp (Fig. 2A). By western blot we detected a main
band of ,165 KDa in lysates from control megakaryocytes,
presumably native Podxl, and other immunoreactive bands of
smaller size. In contrast, no immunoreactive signals were detected in
lysates from Podxl-null mice (Fig. 2B, left panel). The absence of
immunoreactive bands suggests that the smaller bands detected in
the control could be partially glycosylated Podxl. Podxl-null
megakaryocytes showed no reactivity against anti-Podxl, whereas
the control cells showed a strong staining all over the plasma
membrane (Fig. 2B, right panel). The pattern of phalloidin staining
indicates a similar distribution of the cytoskeleton in both conditions.
Hemograms showed no statistical differences between the
controls and Podxl-null mice (results not shown).
Number and function of megakaryocytes
To determine the number and shape of megakaryocytes,
longitudinal sections of decalcified femurs were stained with Giemsa
and the number and areas of megakaryocytes from several sections
were analyzed using the ImageJ software. In vitro differentiated
megakaryocyteswerestainedwithGiemsaandanalyzedasdescribed
in Methods. The number of megakaryocytes per bone marrow
surface area in the Podxl-null mice did not differ from the control.
To assess the maturation of megakaryocytes we distributed the
megakaryocytes in groups according to sizes ranging from 10 to
60 mm. The number of megakaryocytes in control and podxl-null
mice showed no significant differences, neither in decalcified bone
marrow sections nor in megakaryocytes differentiated in vitro
(Figs. 3A,B). Differences in the size-distribution of megakaryocytes
in cultured cells or in bone marrow most likely are the result of
different states of maturation in each case (Figs. 3C,D).
The adherence of cultured megakaryocytes onto immobilized
fibrinogen was similar in controls and Podxl-null megakaryocytes.
Figure 4. Aggregation of control and Podxl-null platelets. (A)
Whole blood-platelet aggregation. Platelet aggregation in whole blood
withdrawn in the presence of PPACK (40 mg/mL) was performed by
measuring the changes in impedance produced by 10 mM ADP or 5 mg/
mL collagen, using a Chrono-Log instrument. Amplitude was the
impedance aggregation at 8 minutes; AU, area under curve. The results
are means +/2SEM of seven different observations in each group. (B)
Collagen-induced aggregation of isolated platelets. Representative
aggregation traces from control and Podxl-null platelets treated with
collagen (5 mg/mL) as described in Methods. Arrows indicate the
addition of the agonist. The graph represents the aggregation values
and means from 6 mice of each genotype. No statistical differences
were observed.
doi:10.1371/journal.pone.0026025.g004
Table 3. Platelet content of surface receptors.
aIIbb3 GPIba GPVI GPIa
Control 50.8679 . 1 61.5 3.1460.05 5.3560.43
Podxl-null 49.6669 . 0 61.2 3.0360.07 5.7060.52
Platelets rich plasma was incubated with anti-GPIba-DyLight649 antibody
(Xia.G5), anti-aIIbb3-FITC (Leo.F2), FITC-labeled rat anti-mouse GPVI and FITC-
labeled rat anti-mouse integrin alpha2 chain (CD49b) or control isotype-
matched mouse IgGs for 30 minutes at room temperature (Emfret Analytics,
Eibelstadt, Germany). The samples were then washed, fixed with 1% PFA, and
analyzed in a cytometer EPICS XL FACS. The results are means 6SEM of 4
different observations in duplicate. Not significant differences were detected
between control and Podxl-null platelets.
doi:10.1371/journal.pone.0026025.t003
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in both cases (Figs. 3E,F). In agreement with these data, the
polyploidy of Podxl-null cultured megakaryocytes did not differ
from the control (Figs. 3G,H).
Bleeding and experimental thrombosis
In view that Podxl seems to enhance the cellular motility and
cellular interactions [16,26] we studied whether the loss of Podxl
would alter the platelet function. We found that bleeding time in
Podxl-null mice increased by 87% over the control values, and
that the carotid closure time induced by ferric chloride was almost
double in Podxl-null than in control mice (Table 1). Moreover, the
acute systemic thrombosis induced by (i.v.) injection of a mixture
of collagen and phenylephrine produced a significantly smaller
reduction in the number of circulating platelets in Podxl-null mice
than in the controls (Table 2).
The platelet content of aIIbb3, GPIb-V-IX, GPVI and integrin
alpha2 chain(CD49b)receptors in Podxl-null mice was similar to that
of controls (Table 3) but the aggregation of Podxl-null platelets,
analyzed in PPACK-uncoagulated whole blood, showed diminished
(30–40%) responses to either ADP or collagen (Fig. 4A). However, no
significant differences were detected between control and Podxl-null
miceinthecollagen-inducedaggregationofisolatedplatelets(Fig.4B).
The agonist-induced activation of washed platelets, assessed by
measuring the binding of the activation-sensitive antibody JON/A
or the surface exposure of P-selectin, was similar in Podxl-null and
control platelets (Fig. 5). Moreover, the surface exposure of
phosphatidylserine, as indicated by the binding of annexin V-FITC
after collagen(5 mg/mL) orthrombin (1 U/mL) activation, was also
similar in Podxl-null and control platelets (results not shown).
Platelet adhesion under static conditions and under flow
Figs. 6A,B show that static adhesion stimulated by 10 mM ADP
was similar in control and Podxl-null washed platelets, and that in
both cases platelets showed morphological features of activation.
For adhesion experiments under flow, citrate-uncoagulated
blood diluted with Tyrode’s buffer was perfused in plastic parallel
flow chambers coated with fibrinogen at an estimated shear stress
of 5 dyne/cm
2 (Figs. 6C,F,G) or 20 dyne/cm
2 (Figs. 6D,E). The
plates perfused with Podxl-null mice blood showed a statistical
significant decrease in the number of aggregates.
Similar results were obtained when calcein-labeled platelets
were perfused under high shear stress ($20 dyne/cm
2)i na
parallel flow chamber coated with collagen. In five different
experiments, the adhesion of Podxl-null platelets to collagen was
approximately 40% of the control values (Fig. 7).
Discussion
Podocalyxin (Podxl) is a heavily sialylated and sulfated plasma
membranesialoprotein.ToinvestigatethefunctionalroleofPodxlin
platelets we have generated mice with a megakaryocyte-restricted
deletion of the podxl gene. The ablation of the podxl gene was verified
by PCR amplification of genomic DNA from megakaryocytes
differentiated in vitro. The efficiency of Pf4-Cre in the recombination
of floxed genes was further verified by measuring Podxl protein in
megakaryocyte lysates. The platelet Podxl-null mice showed normal
rates of growth and fertility with no apparent phenotypical traits.
The blood cell counts, number of bone marrow megakaryocytes,
polyploidy and proplatelet formation did not show statistical
differences between the Podxl-null mice and the controls. Despite
Figure 5. Effect of agonists on the surface exposure of P-selectin or binding of activation dependent antibody JON/A. To determine
the platelet responsiveness to agonists we used washed platelets incubated with ADP, collagen or thrombin at the indicated concentrations. Surface
exposure of P-Selectin (A) and state of activation of aIIbb3 (binding of antibody JON/A) (B) were analyzed by flow cytometry. At least 4 experiments
were performed and the values are means 6SEM.
doi:10.1371/journal.pone.0026025.g005
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bleeding time, reduced platelet aggregation in response to ADP or
collagen, retardation of the ferric chloride-induced closure of the
carotid artery and a significant decreased in the thrombogenic
response in vivo induced by (i.v.) injection of collagen and
phenylephrine. Moreover, adherence and formation of aggregates
onto fibrinogen or collagen-coated plates in a whole blood perfusion
system was reduced in Podxl-null platelets compared to the controls.
Figure 6. Adherence of platelets to immobilized fibrinogen
under parallel flow perfusion conditions. Platelets from control
(A) and Podxl-null mice (B) were allowed to adhere onto fibrinogen-
coated plates for 30 minutes, fixed and labeled with anti-aIIbb3. For
adhesion under flow, blood was diluted 1:2 with Tyrode’s buffer and
perfused by aspiration through a parallel plastic chamber coated with
fibrinogen at an estimated shear stress of 5 dyne/cm
2 (C,F,G) or
20 dyne/cm
2 (D,E). The adhesion of platelets and formation of
aggregates was quantified by the analysis of images using the software
ImageJ (http://rsb.info.nih.gov/ij/) as described in Methods. Represen-
tative images of platelet adhesion under shear stress of 5 dyne/cm
2 in
control (F) and Podxl-null mice (G).
doi:10.1371/journal.pone.0026025.g006
Figure 7. Adherence of platelets to immobilized collagen
perfused through a parallel flow chamber. Control or Podxl-null
platelets were labeled with calcein-AM, diluted with Tyrode’s buffer,
and perfused by aspiration through a parallel plastic chamber coated
with collagen at an estimated shear stress of 20 dyne/cm
2. The
adhesion of platelets and formation of aggregates was quantified
either by the analysis of images using the software ImageJ or by
washing the perfusion chamber with DMSO and measuring the
fluorescence intensity, as described in Methods. The lower panels show
representative images of control and Podxl-null platelet aggregates.
doi:10.1371/journal.pone.0026025.g007
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megakaryocytes altered the control of hemostasis. To note,
overexpression of Podxl in megakaryocytes and platelets [27] has
been recently reported to produce just the opposite effects, this is,
decreased bleeding time and increased agonist-induced platelet
aggregation. Thus, these observations reinforce the idea that Podxl
may contribute to the control of hemostasia.
Whatever the mechanism of Podxl action, one should expect a
decreased aggregation of platelets to be caused either by defective or
deficient platelet receptors. However, the platelet content of fibrinogen
receptor (aIIbb3) and von Willebrand factor receptor (GPIb-V-IX) in
Podxl-null platelets was similar to the controls. Moreover, the agonist-
induced activation of washed platelets, as indicated by surface exposure
of P-selectin, binding of the activation-dependent moAb JON/A to
aIIbb3, or membrane exposure of phophatidylserine, did not show
differences between control and Podxl-null platelets.
Since the number of plateletreceptorsand theirability to respond
to agonists in vitro were normal in the Podxl-null mice, then, what is
causing a decreased efficiency of the hemostatic control in the
absence of Podxl?. At least two simultaneous processes are involved
in controlling the hemostasia: firstly, the formation of platelet clots;
secondly, the formation of fibrin clots by the plasma coagulation
sequence. A role for Podxl in fibrin clot formation appears to be
excluded in view that Podxl-null mice showed similar plasma values
of PT and aPTT than the control group.
The adhesion and aggregation of platelets and the thrombo-
genic occlusion of vessels can take place in mice lacking vWF and
fibrinogen [28]. Thus, factors other than interaction of the main
ligands, vWF and fibrinogen, with their respective platelet
receptors must be involved in the formation of a platelet clot.
Moreover, GPIba contributes to arterial thrombosis by mecha-
nisms independent of its main ligand, vWF [29]. The extracellular
protein fibronectin was postulated to be one of these factors, since
reduced plasma fibronectin produced defective thrombus forma-
tion [30]. On the other hand, both plasma and platelet proteins
seem to contribute to vWF/fibrinogen-independent platelet
aggregation [31]. More than 20 cytoplasmic proteins have been
reported to interact with the carboxyterminal (CT) domains of
either aIIb or b3 glycoproteins [32]. Plasma membrane or
transmembrane proteins like CD40L, Gas6, semaphorin 4D
(CD100) or Platelet Endothelial Aggregation Receptor 1 (PEAR1),
have been reported to be involved in the control of thrombus
formation and/or stabilization. These antecedents highlight the
redundancy of the system controlling the hemostasia and give
support to the possibility that Podxl was one more of the factors
controlling the hemostasia acting either directly or through
interactions with other membrane proteins. It should also be
considered that Podxl could influence the coagulation through
interactions with glycoproteins of the coagulation cascade.
Podxl is heavily sialylated and changes in sialic acid content of
platelets have been reported to alter platelet function [33,34].
Even if the loss of platelet Podxl would not change significantly the
total content of sialic acid, the possibility should be considered that
the absence of specific protein interactions could alter the
intracellular platelet signaling. Moreover, the actions of Podxl in
enhancing adhesion and motility were abolished in mutated cells
in which the O-sialylation was impeded [16].
Podxl could also act in controlling aIIbb3 signaling pathway
through cytoplasmic interactions. The CT domain of Podxl is linked
to the cytoskeleton through the scaffold protein EBP50/NHE-RF
(ezrin-binding protein/Na
+H
+ exchange regulatory factor) [18,35]
and colocalizes with vinculin [16]. On the other hand, talin, a
cytosolic protein with a FERM domain is specifically involved in the
activation and linking of integrin aIIbb3 to the actin cytoskeleton
[35–37]. Talin binds vinculin with high affinity [37–40]. Vinculin
and talin are two pivotal components of the focal adhesions that may
indirectly activate integrins. Both, Podxl and aIIbb3, colocalize with
vinculin at the leading edges of the cell and at regions of intercellular
contacts [16]. Thus, it is tempting to speculate that a decrease
functional efficiency of aIIbb3i nP o d x l - n u l lm i c ec o u l da r i s ef r o ma
functional imbalance of FERM and/or scaffold proteins.
Stable transfection of human Podxl in CHO cells enhances cell
adhesion, motility and cellular interactions in a selectin and integrin-
dependent manner, suggesting that Podxl could act as a co-activator
of platelet aIIbb3 [16]. On high endothelial venules, Podxl is
involved in lymphocyte homing through L-selectin interactions [18].
Since the Podxl effects on cell adhesion are selectin-dependent, the
possibility should also be considered that Podxl-selectin interactions
would be a significant factor in the control of hemostasis.
To conclude, mice with null-Podxl megakaryocytes generated
by the Cre/LoxP gene targeting methodology showed perturbed
hemostatic reponses: increased bleeding time, diminished aggre-
gation of platelets in response to agonists, retarded ferric chloride-
induced closure of the carotid artery, decreased systemic
thrombosis and decreased adhesion and formation of platelet
aggregates under parallel flow conditions. Since Podxl-null
platelets showed normal receptors content and normal activation
by agonists in vitro, the perturbation of hemostasis in the absence of
Podxl could be the result of a decreased efficiency of platelet
adhesiveness produced by the loss of sialic acid and/or selectin-
dependent interactions.
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